There have been conflicting reports about the role of ER-β in breast cancer [27,58,59,60], due to differences between studies; this could be related to the lack of standardized detection methods and insufficiently validated antibodies [43,61,62]. The gene discussed is ESR2; the disease is breast carcinoma.